Billionaire Profile
Robert Duggan
Global Rank
#298

Image: KellyMorfopoulos | CC BY-SA 4.0 | via Wikimedia Commons

Robert Duggan

CEO, Pharmaceuticals
UNITED STATES
Real-Time Net Worth
$10.666B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
-2.1% (24h)
Age
81
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
UNITED STATES

Biography

Robert W. Duggan, born in 1944, is an American entrepreneur, investor, and biotech executive. His estimated net worth is $16 billion as of September 2024. Duggan's wealth stems from his significant involvement in the pharmaceutical industry. He is known for his strategic investments and leadership, notably as the former CEO of Pharmacyclics, where he oversaw the development of the cancer drug Imbruvica, leading to its $21 billion acquisition by AbbVie in 2015. Duggan is currently the CEO and largest shareholder of Summit Therapeutics, focusing on innovative treatments for infectious diseases. His career also includes leadership roles at Computer Motion and involvement in various other successful ventures, demonstrating a long-standing record of turning around and growing companies. Duggan is also known for his philanthropy, including significant donations to the Church of Scientology.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Robert W. Duggan was born in Oakland, California, in 1944. He grew up in a modest household, the third of five children. His father was an industrial engineer, and his mother was a nurse. Duggan studied at the University of California, Santa Barbara, and later at UCLA, focusing on business and economics, but did not complete a degree.

Rise to Success

Duggan's entrepreneurial journey began in 1971 when he invested in Sunset Designs, a children's embroidery company. He later founded Paradise Bakery in 1976, which secured partnerships to supply cookies to McDonald's, Disney World, and KFC. He was CEO of Computer Motion from 1997 to 2003. Duggan's most notable achievement is arguably his role at Pharmacyclics, where he served as CEO and chairman from 2008 to 2015. He transformed the struggling biopharmaceutical company into a billion-dollar enterprise, primarily through the success of the cancer drug Imbruvica. In 2015, AbbVie acquired Pharmacyclics for $21 billion, netting Duggan a substantial profit. In 2020, Duggan invested in Summit Therapeutics and is now the largest shareholder and co-CEO.

Key Business Strategies

Duggan's success is attributed to his ability to identify promising ventures and his effective leadership in turning around struggling companies. He focuses on patient-friendly, science-based solutions, and he's known for making significant, strategic investments in biotechnology and healthcare companies. Duggan often takes a hands-on approach to management, leading the companies he invests in and working to improve their business strategies and innovation.

Philanthropy

Duggan is involved in various philanthropic endeavors. He has donated millions to the Church of Scientology. He has also funded educational initiatives, including athletic departments and faculty chair positions at the University of California, Santa Barbara.

Career Milestones

1971

Sunset Designs

Invested in a children's embroidery company.

1976

Paradise Bakery

Founded Paradise Bakery.

1997

Computer Motion

CEO of Computer Motion

2008

Pharmacyclics

CEO of Pharmacyclics.

2015

AbbVie Acquisition

Pharmacyclics acquired by AbbVie for $21 billion.

2020

Summit Therapeutics

Invested in and became the CEO of Summit Therapeutics.

Philanthropy & Social Impact

Religious

Church of Scientology

$360M+

Donations to the Church of Scientology.

Education

UC Santa Barbara

Unknown

Funding athletic departments and faculty chair positions.

Business Philosophy & Leadership

Notable Quotes

"Robert Duggan's aim in business is "to work for the betterment of all involved"."

Leadership Principles

Patient-Friendly Solutions

Focusing on breakthrough solutions to complex diseases.

Strategic Investment

Identifying promising ventures and making significant investments in biotechnology and healthcare.

Hands-on Management

Leading the companies he invests in and working to improve business strategies and innovation.